SNWV SANUWAVE Health, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1417663 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY0.1%
TTM net income YoY128.0%
TTM EPS YoY76.9%
Revenue 3-yr CAGR29.5%
Net income 3-yr CAGR—
Margins
Gross margin76.0%
Operating margin-4.5%
Net margin6.3%
FCF margin6.3%
EBITDA margin-1.7%
Returns
ROE—
ROA7.6%
ROIC (approx.)-124.0%
Asset turnover1.20x
Leverage & solvency
Liabilities / assets91.2%
Debt / equity0.00x
Current ratio1.18x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.28x
Accruals ratio-2.1%
Payout ratio—
Capex / revenue1.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $44.05M | $32.63M |
| Cost of revenue | $10.08M | $8.08M |
| Gross profit | $33.97M | $24.55M |
| R&D expense | $1.35M | $673,000 |
| SG&A expense | $19.37M | $12.92M |
| Operating income | $4.95M | $3.85M |
| Interest expense | — | $12.56M |
| Pretax income | $11.90M | -$33.06M |
| Income tax | $86,000 | $27,000 |
| Net income | $11.81M | -$33.08M |
| EBITDA | $5.92M | $4.64M |
| EPS (basic) | 1.38 | -7.41 |
| EPS (diluted) | 0.41 | -7.41 |
| Weighted avg. shares (diluted) | 9.08M | 4.46M |
| Balance sheet | ||
| Cash & equivalents | $11.96M | $10.24M |
| Receivables | $5.42M | $3.33M |
| Inventory | $5.93M | $4.15M |
| Current assets | $24.63M | $18.40M |
| PP&E, net | $1.97M | $303,000 |
| Goodwill | $7.26M | $7.26M |
| Intangibles | $3.03M | $3.73M |
| Total assets | $37.34M | $30.12M |
| Current liabilities | $17.85M | $45.42M |
| Short-term debt | $5.75M | — |
| Long-term debt | $16.14M | — |
| Total debt | $21.89M | — |
| Total liabilities | $35.72M | $45.91M |
| Shareholders' equity | $1.62M | -$15.79M |
| Net debt | $9.93M | — |
| Shares outstanding | 8.59M | 8.54M |
| Cash flow statement | ||
| Operating cash flow | $3.88M | $2.46M |
| Capital expenditure | $1.94M | $490,000 |
| Free cash flow | $1.93M | $1.97M |
| Investing cash flow | $3.43M | -$490,000 |
| Financing cash flow | -$5.59M | $6.35M |
| Depreciation & amortization | $974,000 | $788,000 |
| Stock-based compensation | $4.85M | $1.51M |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.